Stay updated on Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4, indicating a new page build. The change reflects release metadata rather than content updates to the study record.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe record history page shows a new revision label (v3.5.3) replacing the previous v3.5.2, indicating a fresh release of the page's UI and metadata. This is a metadata update rather than a change to study content.SummaryDifference0.1%

- Check39 days agoChange DetectedA new revision entry v3.5.2 was added and the previous revision v3.5.0 was removed from the history.SummaryDifference0.1%

- Check68 days agoChange DetectedRevision v3.5.0 was added and Revision v3.4.3 was removed from the record history.SummaryDifference0.1%

- Check75 days agoChange DetectedA new Revision: v3.4.3 entry was added to the history, and the previous Revision: v3.4.2 entry was removed.SummaryDifference0.1%

- Check104 days agoChange DetectedA new Revision: v3.4.2 has been added, and earlier entries including a government-funding notice and Revision: v3.4.1 have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

Stay in the know with updates to Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.